argenx

Antibody
#Antibodies #argenx #Biology #Biotechnology #Drug development #Drug discovery #Muscles

argenx advances ARGX-119 in congenital myasthenic syndromes 

argenx has announced it will advance ARGX-119, a first-in-class agonist antibody to muscle-specific kinase (MuSK), to a registrational study in patients with congenital myasthenic syndromes (CMS). The decision follows the analysis of topline data from the Phase Ib study, in which ARGX-119 demonstrated a favourable safety and tolerability profile. “The… Read More

#News

Autoantibodies bond to receptor (achr) blocking the acetylcholine transmitters in Myasthenia gravis (MG).
#Antibody Fragments #argenx #Autoimmune disease #Events #Neurology

Antibody fragment shows promise in myasthenia gravis

argenx shared trial and real-world data on Vyvgart (efgartigimod alfa) in patients with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive at the European Academy of Neurology (EAN) Annual Meeting. In gMG, Vyvgart demonstrated consistent and repeatable improvements across patient subtypes, a… Read More

#News